Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.
Disease progression
Forced vital capacity
Home spirometry
Idiopathic pulmonary fibrosis
Interstitial lung disease
Variability
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
19 Oct 2020
19 Oct 2020
Historique:
received:
26
02
2020
accepted:
25
09
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
6
8
2021
Statut:
epublish
Résumé
Fibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has few predictors of progression. Daily home spirometry has been proposed to provide important information about the clinical course of idiopathic pulmonary disease (IPF). However, experience is limited, and home spirometry is not a routine component of patient care in ILD. Using home spirometry, we aimed to investigate the predictive potential of daily measurements of forced vital capacity (FVC) in fibrotic ILD. In this prospective observational study, patients with fibrotic ILD and clinical progression were provided with home spirometers for daily measurements over 6 months. Hospital based spirometry was performed after three and 6 months. Disease progression, defined as death, lung transplantation, acute exacerbation or FVC decline > 10% relative was assessed in the cohort. From May 2017 until August 2018, we included 47 patients (IPF n = 20; non-IPF n = 27). Sufficient daily measurements were performed by 85.1% of the study cohort. Among these 40 patients (IPF n = 17; non-IPF n = 23), who had a mean ± SD age of 60.7 ± 11.3 years and FVC 64.7 ± 21.7% predicted (2.4 ± 0.8 L), 12 patients experienced disease progression (death: n = 2; lung transplantation: n = 3; acute exacerbation: n = 1; FVC decline > 10%: n = 6). Within the first 28 days, a group of patients had high daily variability in FVC, with 60.0% having a variation ≥5%. Patients with disease progression had significantly higher FVC variability than those in the stable group (median variability 8.6% vs. 4.8%; p = 0.002). Cox regression identified FVC variability as independently associated with disease progression when controlling for multiple confounding variables (hazard ratio: 1.203; 95% CI:1.050-1.378; p = 0.0076). Daily home spirometry is feasible in IPF and non-IPF ILD and facilitates the identification of FVC variability, which was associated with disease progression.
Sections du résumé
BACKGROUND
BACKGROUND
Fibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has few predictors of progression. Daily home spirometry has been proposed to provide important information about the clinical course of idiopathic pulmonary disease (IPF). However, experience is limited, and home spirometry is not a routine component of patient care in ILD. Using home spirometry, we aimed to investigate the predictive potential of daily measurements of forced vital capacity (FVC) in fibrotic ILD.
METHODS
METHODS
In this prospective observational study, patients with fibrotic ILD and clinical progression were provided with home spirometers for daily measurements over 6 months. Hospital based spirometry was performed after three and 6 months. Disease progression, defined as death, lung transplantation, acute exacerbation or FVC decline > 10% relative was assessed in the cohort.
RESULTS
RESULTS
From May 2017 until August 2018, we included 47 patients (IPF n = 20; non-IPF n = 27). Sufficient daily measurements were performed by 85.1% of the study cohort. Among these 40 patients (IPF n = 17; non-IPF n = 23), who had a mean ± SD age of 60.7 ± 11.3 years and FVC 64.7 ± 21.7% predicted (2.4 ± 0.8 L), 12 patients experienced disease progression (death: n = 2; lung transplantation: n = 3; acute exacerbation: n = 1; FVC decline > 10%: n = 6). Within the first 28 days, a group of patients had high daily variability in FVC, with 60.0% having a variation ≥5%. Patients with disease progression had significantly higher FVC variability than those in the stable group (median variability 8.6% vs. 4.8%; p = 0.002). Cox regression identified FVC variability as independently associated with disease progression when controlling for multiple confounding variables (hazard ratio: 1.203; 95% CI:1.050-1.378; p = 0.0076).
CONCLUSIONS
CONCLUSIONS
Daily home spirometry is feasible in IPF and non-IPF ILD and facilitates the identification of FVC variability, which was associated with disease progression.
Identifiants
pubmed: 33076914
doi: 10.1186/s12931-020-01524-8
pii: 10.1186/s12931-020-01524-8
pmc: PMC7574190
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Subventions
Organisme : Lungenfibrose eV
ID : 2018
Organisme : Friedrich-Baur-Stiftung
ID : 50/16
Organisme : Boehringer Ingelheim
ID : AZ_522-17
Références
J Pers Med. 2019 May 05;9(2):
pubmed: 31060343
Eur Respir J. 2012 Jul;40(1):93-100
pubmed: 22135282
Pneumologie. 2016 Nov;70(11):742-746
pubmed: 27652583
Thorax. 2012 Sep;67(9):804-10
pubmed: 22555278
Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66
pubmed: 21616999
Chest. 2008 Dec;134(6):1265-1270
pubmed: 18689595
Thorax. 2012 May;67(5):407-11
pubmed: 22426899
BMC Pulm Med. 2017 Jul 25;17(1):104
pubmed: 28743305
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679608
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Eur Respir J. 2007 Jun;29(6):1256-76
pubmed: 17540788
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Am J Respir Crit Care Med. 2020 Aug 1;202(3):393-401
pubmed: 32325005
Eur Respir J. 2011 Feb;37(2):356-63
pubmed: 20595144
Am J Respir Crit Care Med. 2016 Oct 15;194(8):989-997
pubmed: 27089018
Front Med (Lausanne). 2017 Oct 23;4:176
pubmed: 29109947
ERJ Open Res. 2020 Apr 06;6(1):
pubmed: 32280666
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Chest. 2011 Jul;140(1):221-229
pubmed: 21729893
Arch Intern Med. 1982 Jul;142(7):1287-91
pubmed: 7092446
Respir Res. 2018 May 29;19(1):105
pubmed: 29843728
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
Respir Res. 2017 Jan 17;18(1):18
pubmed: 28095852
Am J Respir Crit Care Med. 2007 Apr 1;175(7):705-11
pubmed: 17218621
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
Pneumologie. 2007 Jan;61(1):52-6
pubmed: 17253211
Eur Respir J. 2010 Apr;35(4):830-6
pubmed: 19840957
Chest. 2007 Jul;132(1):214-20
pubmed: 17400667
Am J Respir Crit Care Med. 2015 Jul 15;192(2):209-18
pubmed: 25922973